Advanced Search

 

Study ID Status Title Patient Level Data
AK130926 Completed A Multicenter, Double-Blind, Randomized, Placebo Controlled Comparison of the Effects on Sexual Functioning of Extended-Release Bupropion Hydrochloride (300-450mg) and escitalopram (10-20mg) in Outpatients with Moderate to Severe Major Depression over an Eight-Week Treatment Period
AK130927 Completed A Multicenter, Double-blind Randomized Placebo-controlled Comparison of the Effects on Sexual Functioning of Extended-release Bupropion Hydrochloride (300-450mg) and Escitalopram (10-20mg) in Outpatients with Moderate to Severe Major Depression over an Eight-Week Treatment Period
AK130930 Completed A 7-Month, Multicenter, Randomized, Double-Blind, Placebo-Controlled Comparison of 150-300mg/day of Extended-Release Bupropion Hydrochloride (WELLBUTRIN XL) and Placebo for the Prevention of Seasonal Affective Disorder in Subjects with a History of Seasonal Affective Disorder Followed by an 8-Week Observational Follow-up Phase
AK130931 Completed An 8 week, multicenter, randomized, double-blind, placebo controlled comparison of the efficacy of extended release bupropion hydrochloride and placebo in the treatment of adult outpatients with major depressive disorder with lethargic symptoms
AK130934 Completed An 8-week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Comparison of Extended-Release Bupropion Hydrochloride 300-450 mg/day to Assess the Efficacy, Safety, and Effects on Health Outcomes in the Treatment of Adults with Attention-Deficit/Hyperactivity Disorder
AK130936 Completed A 7 Month, Multicenter, Randomized, Double-blind, Placebo-Controlled Comparison of 150-300 mg/day of Extended-release Bupropion Hydrochloride and Placebo for the Prevention of Seasonal Affective Disorder in subjects with a History of Seasonal Affective Disorder Followed by an 8-week Observational Follow-up Phase
AK130940 Completed A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible Dose Study to Evaluate the Efficacy, Safety and Tolerability of Extended-release Bupropion Hydrochloride (150mg-300mg once daily) in Elderly Subjects with Major Depressive Disorder
AKT106757 Terminated An Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the AKT Inhibitor GSK690693 given on Various Schedules in Subjects with Solid Tumors or Lymphoma Study Listed on ClinicalStudyDataRequest.com
AKT108169 Withdrawn A Phase I Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Potential Anti-cancer Activity of the AKT Inhibitor GSK690693 in Subjects with Relapsed or Refractory Hematologic Malignancies
ALB110247 Completed Randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of Retapamulin ointment, 1% applied twice daily for 3 or 5 days to the anterior nares of healthy adult subjects nasally colonized with Staphylococcus aureus Study Listed on ClinicalStudyDataRequest.com
AMB107623 Completed Phase I study of ambrisentan – Single dose study in healthy Japanese male subjects
AMB107816 Completed Study AMB107816, Clinical Evaluation of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension (PAH)- An Open-Label Phase II/III Study to evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A -<Classification: Exploratory and confirmatory clinical trial>
AMB107818 Completed Study AMB107818, Clinical Evaluation of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension (PAH)- An open label Study of GSK1325760A to evaluate the Safety and Efficacy of GSK1325760A - a Long-term Extension Study -
APV 20003 Completed A 48 Week, Phase II, Open-Label Multi-Cohort, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GW433908/Ritonavir QD and GW433908/Ritonavir BID when Administered to HIV-1 Infected, Antiretroviral Naive and Experienced, Pediatric Subjects 2-18 Years Old
APV10017 Completed A Phase I, Parallel, Open-label, Multicenter, Two-Week, Repeat-dose Study Evaluating Plasma Amprenavir Pharmacokinetics in HIV-1-infected Adult Subjects with Mild, Moderate or Severe Hepatic Impairment Receiving Fosamprenavir + Ritonavir Compared to Matched Control Subjects with Normal Hepatic Function
APV102002 Completed A Phase III, Randomized, Controlled, Open-label, Multicentre, Three Arm Study to Compare the Efficacy and Safety of a Dual-boosted HIV-1 Protease Inhibitor regimen of Fosamprenavir/Lopinavir/Ritonavir 1400mg/533mg/133mg Twice Daily and an Increased Dosage Regimen of FPV/RTV 1400mg/100mg BID Versus the Standard Dosage Regimen of FPV/RTV 700mg/100mg BID for 24 Weeks in Multiple-PI Experienced, HIV-infected Adults Experiencing Virological Failure
APV109141 Completed Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir, Administered with Abacavir/Lamivudine Once-Daily in Antiretroviral-Naive HIV-1 Infected Adult Subjects.
APV20002 Active, Not Recruiting A 48 week, Phase II, open-label, 2-cohort, multicenter study to evaluate the pharmacokinetics, safety, tolerability and antiviral activity of GW433908 and GW433908/RTV when administered to HIV-1 infected protease inhibitor (PI) naive and PI-experienced pediatric subjects aged 4 weeks to <2 years.
APV29005 Completed A 48 Week, Phase II, Non-Comparative, Open-label, Multi-Cohort, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GW433908/Ritonavir BID when Administered to HIV-1 infected, PI-Naïve and Experienced, Pediatric Subjects, 2 to 18 Years Old and of GW433908 BID Administered to PI-Naïve, Pediatric Subjects 2 to < 6 Years Old
APV30005 Completed An Open-Label Phase III Study to Assess the Long Term Safety Profile of GW433908 Containing Regimens in HIV-1 Infected Subjects
APV30007 Completed A 24 week Phase IIIb/IV single arm open label observational study to explore the efficacy of protease inhibitors given in combination with reverse transcriptase inhibitors to HIV-1 infected subjects with protease mutations selected during therapy with GW433908 containing antiretroviral therapy
APV40005 Completed An open-label phase III study to provide access to fosamprenavir and to assess the long term safety and tolerability of fosamprenavir containing regimens in HIV Infected patients with limited treatment options
AR3106116 Completed Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in Prevention of Venous Thromboembolism (VTE) after Abdominal Surgery
AR3106333 Completed Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in Prevention of Venous Thromboembolism after Elective Total Hip Replacement Surgery
AR3106335 Completed Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in Prevention of Venous Thromboembolism after Hip Fracture Surgery

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.